163 related articles for article (PubMed ID: 26471257)
1. Canakinumab in adults with steroid-refractory pyoderma gangrenosum.
Kolios AG; Maul JT; Meier B; Kerl K; Traidl-Hoffmann C; Hertl M; Zillikens D; Röcken M; Ring J; Facchiano A; Mondino C; Yawalkar N; Contassot E; Navarini AA; French LE
Br J Dermatol; 2015 Nov; 173(5):1216-23. PubMed ID: 26471257
[TBL] [Abstract][Full Text] [Related]
2. An open-label pilot study of alefacept for the treatment of pyoderma gangrenosum.
Foss CE; Clark AR; Inabinet R; Camacho F; Jorizzo JL
J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):943-9. PubMed ID: 18384543
[TBL] [Abstract][Full Text] [Related]
3. Use of infliximab in pyoderma gangrenosum.
Hewitt D; Tait C
Australas J Dermatol; 2007 May; 48(2):95-8. PubMed ID: 17535196
[TBL] [Abstract][Full Text] [Related]
4. Clinical Disease Patterns in a Regional Swiss Cohort of 34 Pyoderma Gangrenosum Patients.
Kolios AGA; Gübeli A; Meier B; Maul JT; Kündig T; Nilsson J; Hafner J; Guenova E; Kerl K; Anliker M; Kempf W; Navarini AA; French LE; Cozzio A
Dermatology; 2017; 233(4):268-276. PubMed ID: 29130957
[TBL] [Abstract][Full Text] [Related]
5. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
[TBL] [Abstract][Full Text] [Related]
6. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.
Brooklyn TN; Dunnill MG; Shetty A; Bowden JJ; Williams JD; Griffiths CE; Forbes A; Greenwood R; Probert CS
Gut; 2006 Apr; 55(4):505-9. PubMed ID: 16188920
[TBL] [Abstract][Full Text] [Related]
7. Poor prognosis of arthritis-associated pyoderma gangrenosum.
Charles CA; Bialy TL; Falabella AF; Eaglstein WH; Kerdel FA; Kirsner RS
Arch Dermatol; 2004 Jul; 140(7):861-4. PubMed ID: 15262699
[TBL] [Abstract][Full Text] [Related]
8. Treatment of idiopathic pyoderma gangrenosum with infliximab: induction dosing regimen or on-demand therapy?
Adişen E; Oztaş M; Gürer MA
Dermatology; 2008; 216(2):163-5. PubMed ID: 18216480
[TBL] [Abstract][Full Text] [Related]
9. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome.
de Koning HD; Schalkwijk J; van der Ven-Jongekrijg J; Stoffels M; van der Meer JW; Simon A
Ann Rheum Dis; 2013 Oct; 72(10):1634-8. PubMed ID: 23087179
[TBL] [Abstract][Full Text] [Related]
10. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody.
Tan MH; Gordon M; Lebwohl O; George J; Lebwohl MG
Arch Dermatol; 2001 Jul; 137(7):930-3. PubMed ID: 11453813
[TBL] [Abstract][Full Text] [Related]
11. An update on adalimumab for pyoderma gangrenosum.
Yamamoto T
Drugs Today (Barc); 2021 Sep; 57(9):535-542. PubMed ID: 34586101
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.
Gottlieb AB; Kalb RE; Blauvelt A; Heffernan MP; Sofen HL; Ferris LK; Kerdel FA; Calabro S; Wang J; Kerkmann U; Chevrier M
J Am Acad Dermatol; 2012 Oct; 67(4):642-50. PubMed ID: 22153792
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results).
Imagawa T; Nishikomori R; Takada H; Takeshita S; Patel N; Kim D; Lheritier K; Heike T; Hara T; Yokota S
Clin Exp Rheumatol; 2013; 31(2):302-9. PubMed ID: 23380020
[TBL] [Abstract][Full Text] [Related]
14. A case of refractory pyoderma gangrenosum treated with a combination of Apligraf and systemic immunosuppressive agents.
Duchini G; Itin P; Arnold A
Adv Skin Wound Care; 2011 May; 24(5):217-20. PubMed ID: 21505282
[TBL] [Abstract][Full Text] [Related]
15. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis).
Marzano AV; Damiani G; Ceccherini I; Berti E; Gattorno M; Cugno M
Br J Dermatol; 2017 Jun; 176(6):1588-1598. PubMed ID: 27943240
[TBL] [Abstract][Full Text] [Related]
16. Topical tacrolimus for the treatment of localized, idiopathic, newly diagnosed pyoderma gangrenosum.
Marzano AV; Trevisan V; Lazzari R; Crosti C
J Dermatolog Treat; 2010 May; 21(3):140-3. PubMed ID: 19903010
[TBL] [Abstract][Full Text] [Related]
17. Systemic pyoderma gangrenosum responding to infliximab and adalimumab.
Hubbard VG; Friedmann AC; Goldsmith P
Br J Dermatol; 2005 May; 152(5):1059-61. PubMed ID: 15888172
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Twenty-six-week phase 3 open-label study.
Yamasaki K; Yamanaka K; Zhao Y; Iwano S; Takei K; Suzuki K; Yamamoto T
J Dermatol; 2020 Dec; 47(12):1383-1390. PubMed ID: 32804433
[TBL] [Abstract][Full Text] [Related]
19. Treatment of pyoderma gangrenosum with methotrexate.
Teitel AD
Cutis; 1996 May; 57(5):326-8. PubMed ID: 8726713
[TBL] [Abstract][Full Text] [Related]
20. Pyoderma gangrenosum--rebel without a cure?
Jacob SE; Weisman RS; Kerdel FA
Int J Dermatol; 2008 Feb; 47(2):192-4. PubMed ID: 18211497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
